2014
The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer
Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J. The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer. Molecular Cell 2014, 57: 191-201. PMID: 25544564, PMCID: PMC4764128, DOI: 10.1016/j.molcel.2014.11.021.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBaculoviridaeBinding SitesCrystallography, X-RayEnzyme ActivationHumansLigandsMiceModels, MolecularMutationNeoplasmsNIH 3T3 CellsProtein BindingProtein FoldingProtein Interaction Domains and MotifsProtein MultimerizationProtein Structure, SecondaryProto-Oncogene Proteins c-kitRecombinant ProteinsSf9 CellsSpodopteraConceptsOncogenic KIT mutationsKIT mutationsGastrointestinal stromal tumorsAcute myeloid leukemiaKIT tyrosine kinase activitySomatic oncogenic mutationsInterstitial pacemaker cellsLigand-dependent stimulationReceptor tyrosine kinase KITStromal tumorsTyrosine kinase KITMyeloid leukemiaReceptor activationPacemaker cellsTyrosine kinase activityCancerKinase KITOncogenic mutationsHematopoietic cellsGerm cellsOncogenic activationActivationCellsReceptor moleculesMutations
2013
Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region
Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J. Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 17832-17837. PMID: 24127596, PMCID: PMC3816449, DOI: 10.1073/pnas.1317118110.Peer-Reviewed Original ResearchConceptsKIT antibodyReceptor tyrosine kinase inhibitionGastrointestinal stromal tumorsAcute myeloid leukemiaDurable disease controlTyrosine kinase inhibitorsTyrosine kinase inhibitionSomatic oncogenic mutationsUnique therapeutic approachClinical progressionStromal tumorsMyeloid leukemiaTherapeutic approachesDramatic responseTreatment of KITDrug resistanceDisease controlIsolated antibodyKIT inhibitionKinase inhibitorsAntibodiesCancerCell proliferationOncogenic mutationsKinase inhibition